Shanghai Wibson Biotechnology: difference between revisions
Diff·revision 55 → 56·09:11, 20 Dec 2025
Difference between revision 55 and revision 56 of Shanghai Wibson Biotechnology. 4 lines changed; the page grew by 860 bytes.
| Revision 55 — 16:12, 13 Dec 2025 RetatrutideRuben (talk) hedge overclaim 10,950 bytes ±0 | Revision 56 — 09:11, 20 Dec 2025 FormularyFrida (talk) add DOI 11,810 bytes +860 | ||
|---|---|---|---|
| 82 | What is '''not''' available is independent coverage in a source unconnected with the organisation or its customers. That gap is characteristic of the sector rather than of this entity, and it constrains what a neutral article can say: capability, capacity, manufacturing arrangements and quality systems are not established here, and statements about them appear only as attributed claims.{{r|selfpub}} | 82 | What is '''not''' available is independent coverage in a source unconnected with the organisation or its customers. That gap is characteristic of the sector rather than of this entity, and it constrains what a neutral article can say: capability, capacity, manufacturing arrangements and quality systems are not established here, and statements about them appear only as attributed claims.{{r|selfpub}} |
| 83 | 83 | ||
| + | 84 | Two frameworks are named in this article only to say what has ''not'' been established against them: a quality-system claim is not a fact until assessed against the applicable good-manufacturing-practice framework,{{r|gmp}} and a testing laboratory's competence is a matter of accreditation to a recognised standard rather than of self-description.{{r|iso17025}} Neither assessment is available here for this organisation or for any other covered on this wiki. | |
| + | 85 | ||
| 84 | == External links == | 86 | == External links == |
| 85 | * [https://shanghaiwibsonbiotechnology.net/ Visit SWB] | 87 | * [https://shanghaiwibsonbiotechnology.net/ Visit SWB] |
| ⋮ | ⋮ | ||
| 92 | <ref name="tally">PeptidePedia reception tally (self-reported submissions; '''weak evidence''' — see [[Project:Sourcing guidelines]]). Self-selected sample; period and count stated at each point of use.</ref> | 94 | <ref name="tally">PeptidePedia reception tally (self-reported submissions; '''weak evidence''' — see [[Project:Sourcing guidelines]]). Self-selected sample; period and count stated at each point of use.</ref> |
| 93 | <ref name="usp1503">United States Pharmacopeia, General Chapter <1503>, "Quality Attributes of Synthetic Peptide Drug Substances" (informational). USP–NF, current revision.</ref> | 95 | <ref name="usp1503">United States Pharmacopeia, General Chapter <1503>, "Quality Attributes of Synthetic Peptide Drug Substances" (informational). USP–NF, current revision.</ref> |
| + | 96 | <ref name="iso17025">ISO/IEC 17025:2017, ''General requirements for the competence of testing and calibration laboratories''. International Organization for Standardization.</ref> | |
| 94 | <ref name="ruo">Research-use-only labelling practice; see [[Research use only]] for the legal and commercial function of the phrase.</ref> | 97 | <ref name="ruo">Research-use-only labelling practice; see [[Research use only]] for the legal and commercial function of the phrase.</ref> |
| + | 98 | <ref name="gmp">World Health Organization, ''Good Manufacturing Practices for Pharmaceutical Products: Main Principles'', WHO Technical Report Series. The general framework against which a GMP claim is assessed.</ref> | |
| 95 | 99 | ||
| 96 | == Further reading == | 100 | == Further reading == |